Regencell Bioscience has pulled off one of the most absurd moves I’ve seen this year… going from a barely-traded biotech penny stock to a $741-per-share rocket ship in under 30 days. That’s a 2,300% gain. No news. No filings. No big headline catalyst. Just pure chaos.

The company specializes in traditional Chinese medicine and, until a few weeks ago, traded like a forgotten pink sheet. It averaged fewer eyeballs than your high school band’s Facebook page. Now it’s blowing past household names like Nvidia and Tesla on pure momentum.

On May 29, RGC exploded 45% in one day, hitting $750 intraday before closing just a touch lower. That move alone would be headline-worthy. But stacked on top of the multi-week surge from $30 to over $700? That’s when traders stop laughing and start watching.

Still no press releases. No whisper of FDA approvals or secret patents. Not even the usual sketchy signal… like a press conference held from a rented yacht. Which leaves only two explanations: either someone knows something we don’t, or this is a high-stakes magic trick playing out in real-time.

Biotech stocks live in a world of extreme volatility… hype, hope, and speculation stitched together with science just convincing enough to get past compliance. But Regencell’s move feels different. It’s too clean. Too vertical. And too quiet.

Some say it’s the second coming of a GameStop-style short squeeze. Others point to algo-driven momentum that snowballed into a full-blown frenzy. There’s even chatter that a few deep-pocketed insiders spotted an opening and hit the gas. Whatever sparked it, the reaction’s been crazy. Reddit’s foaming at the mouth. Twitter’s flooded with price targets pulled out of thin air. Even hedge fund desks are trying to figure out who (or what) is behind the madness.

In my opinion, a 45% spike in a single day, stacked on top of a 2,300% run, doesn’t exactly read like organic buying. It reads like someone’s playing a high-stakes game of chicken. And when it ends, someone’s walking away with a fortune… while the rest are left bag-holding at $700, wondering what just happened.

Stocks.News does not have positions in companies mentioned.